Parmax Pharma Ltd Stock Price Today (NSE: PARMAX)
Fundamental Score
Parmax Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Parmax Pharma Ltd share price today is ₹136.40, up +0.00% on NSE/BSE as of 22 September 2026. Parmax Pharma Ltd (PARMAX) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹51.03 (Cr). The 52-week high for PARMAX share price is ₹136.40 and the 52-week low is ₹22.60.
Parmax Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Parmax Pharma Ltd share price chart: 25.29% return over the past month. 52-week high ₹136.40, 52-week low ₹22.60.
Parmax Pharma Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹136.40 | ₹136.40 | ₹136.40 | ₹136.40 | 3.92K (Cr) | |
| ₹135.05 | ₹135.05 | ₹135.00 | ₹135.05 | 6.33K (Cr) | |
| ₹133.75 | ₹133.75 | ₹133.75 | ₹133.75 | 2.02K (Cr) | |
| ₹131.15 | ₹131.15 | ₹131.15 | ₹131.15 | 0.00 (Cr) | |
| ₹131.15 | ₹131.15 | ₹131.15 | ₹131.15 | 0.00 (Cr) | |
| ₹131.15 | ₹131.15 | ₹131.15 | ₹131.15 | 0.00 (Cr) | |
| ₹131.15 | ₹131.15 | ₹131.15 | ₹131.15 | 55.00K (Cr) | |
| ₹129.90 | ₹129.90 | ₹129.90 | ₹129.90 | 204.00 (Cr) | |
| ₹127.40 | ₹127.40 | ₹126.80 | ₹127.40 | 5.18K (Cr) | |
| ₹124.95 | ₹124.95 | ₹124.95 | ₹124.95 | 1.28K (Cr) |
Parmax Pharma Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹133.75 | ₹136.40 | ₹133.75 | ₹136.40 | +1.98% | |
| ₹102.70 | ₹131.15 | ₹98.65 | ₹131.15 | +27.70% | |
| ₹79.67 | ₹111.27 | ₹79.67 | ₹104.78 | +31.52% | |
| ₹37.03 | ₹78.11 | ₹37.00 | ₹78.11 | +110.94% | |
| ₹33.50 | ₹43.00 | ₹31.00 | ₹37.03 | +10.54% | |
| ₹31.90 | ₹35.93 | ₹27.45 | ₹30.02 | -5.89% | |
| ₹29.00 | ₹32.97 | ₹22.60 | ₹28.44 | -1.93% | |
| ₹34.71 | ₹39.99 | ₹29.00 | ₹30.20 | -12.99% | |
| ₹33.66 | ₹42.00 | ₹28.40 | ₹36.85 | +9.48% | |
| ₹35.49 | ₹35.89 | ₹29.08 | ₹33.83 | -4.68% | |
| ₹35.19 | ₹35.99 | ₹28.00 | ₹35.49 | +0.85% | |
| ₹31.33 | ₹35.68 | ₹29.30 | ₹34.37 | +9.70% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Parmax Pharma Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Parmax Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of PARMAX across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (387.77%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (323.21%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Suboptimal ROCE (-83.10%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-2.27%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Limited Growth History (-14.28% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (-3.71x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Liquidity Concerns (Current Ratio: 0.77)
Observation: Current assets may not adequately cover short-term liabilities.
Analysis: Current ratio <1.0 raises working capital concerns.
Negative Free Cash Flow (₹-8.10 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Parmax Pharma Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Parmax Pharma Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Parmax Pharma LtdParmax Pharma L...Selected✓ PARMAX • 540359 | 0/100 | ₹136.40₹136 | ₹51.03₹51.03 | — — | — — | -83.10%Poor -83.10% Poor | — — | — — | -14.28%Poor -14.28% Poor | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9425.50₹9426 | ₹249775.75₹249775.75 | 85.52Average 85.5 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4927.00₹4927 | ₹166759.24₹166759.24 | 78.71Average 78.7 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1370.00₹1370 | ₹110675.45₹110675.45 | 32.82Average 32.8 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1925.50₹1926 | ₹104025.14₹104025.14 | 95.04Average 95.0 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1675.20₹1675 | ₹96391.01₹96391.01 | 26.17Average 26.2 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2099.90₹2100 | ₹96017.92₹96017.92 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1141.40₹1141 | ₹95306.90₹95306.90 | 29.50Average 29.5 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2289.10₹2289 | ₹94539.83₹94539.83 | 46.25Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price249775.75 Cr
- Torrent Pharmaceuticals Limited share price166759.24 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110675.45 Cr
Parmax Pharma Ltd Quarterly Performance
Latest quarterly metrics for PARMAX — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
323.21%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
387.77%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-14.28%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Parmax Pharma Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for PARMAX — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Parmax Pharma Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Parmax Pharma Ltd (PARMAX) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Parmax Pharma Ltd
About PARMAX (Parmax Pharma Ltd)
Parmax Pharma Ltd is a dynamic force in the pharmaceutical landscape, pushing the boundaries of chemical innovation and therapeutic solutions. Established with a vision to contribu...te to the well-being of society, Parmax focuses on the meticulous development and production of essential pharmaceutical ingredients. Situated in the heart of India's industrial hub, the company boasts state-of-the-art manufacturing facilities equipped with cutting-edge technology and staffed by a team of experienced scientists and engineers. Parmax Pharma's unwavering commitment to quality, safety, and environmental responsibility is reflected in its stringent adherence to global regulatory standards. The company's dedication extends beyond mere production; it is dedicated to fostering collaborative partnerships with researchers, healthcare providers, and other stakeholders to drive advancements in medical science. At the core of Parmax Pharma's operations lies a diverse portfolio of bulk drugs, advanced drug intermediates, and specialty chemicals, each meticulously crafted to meet the ever-evolving needs of the pharmaceutical industry. The company leverages its extensive research and development capabilities to formulate innovative products that address critical healthcare challenges. Parmax prioritizes sustainable manufacturing practices, ensuring that its operations are environmentally conscious and minimize their ecological footprint. This commitment to sustainability is deeply ingrained in the company's ethos, demonstrating its responsibility towards future generations. From the sourcing of raw materials to the final product release, Parmax Pharma maintains rigorous quality control measures to ensure the efficacy and safety of its offerings. Parmax Pharma stands as a testament to the power of Indian ingenuity and entrepreneurial spirit. From its humble beginnings, the company has steadily grown into a respected player in the global pharmaceutical market. Its success is built on a foundation of scientific excellence, ethical business practices, and a deep-seated commitment to customer satisfaction. Parmax Pharma's story is not just about manufacturing pharmaceuticals; it is about contributing to a healthier future for people around the world. With a clear vision and unwavering dedication, Parmax Pharma is poised to continue its journey of innovation and growth, solidifying its position as a trusted partner in the pursuit of better health.
Company Details
Key Leadership
PARMAX Share Price: Frequently Asked Questions
What is the current share price of Parmax Pharma Ltd?
Parmax Pharma Ltd (PARMAX) trades at ₹136.40 on NSE and BSE. Market cap ₹51.03 (Cr). Educational data only.
What is the P/E ratio of Parmax Pharma Ltd?
Parmax Pharma Ltd has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Parmax Pharma Ltd?
Parmax Pharma Ltd has a Bull Run score of 0/100 based on 25+ financial parameters.
Does Parmax Pharma Ltd pay dividends?
Parmax Pharma Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Parmax Pharma Ltd?
Parmax Pharma Ltd has ROE of N/A. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Parmax Pharma Ltd?
Parmax Pharma Ltd has debt-to-equity of N/A.
Is Parmax Pharma Ltd a good investment?
Bull Run gives Parmax Pharma Ltd a score of 0/100. This is not investment advice — consult a SEBI-registered advisor.